Medrx Co.,Ltd. (4586.T) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	131.0M	128.0M	257.0M	29.0M	59.0M
Cost of Revenue	—	1.2M	300.0K	2.4M	2.6M
Gross Profit	—	126.9M	257.6M	27.1M	56.9M
Operating Expenses
R&D Expense	—	—	—	—	—
SG&A Expense	—	1.1B	1.1B	960.7M	1.2B
General & Admin Expense	—	—	—	—	—
Selling & Marketing Expense	—	—	—	—	—
Other Expenses	—	—	—	—	—
Total Operating Expenses	—	1.1B	1.1B	960.7M	1.2B
Cost and Expenses	899.0M	1.1B	1.1B	962.0M	1.2B
Operating Income (EBIT)	(768.0M)	(941.0M)	(793.0M)	(933.0M)	(1.1B)
Non-Operating
Interest Income	—	2.5M	225.0K	10.0K	17.0K
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	4.5M	38.0M	2.9M	(13.4M)
Non-Operating Income (excl Interest)	—	17.7M	52.8M	14.5M	1.5M
EBT (Pre-Tax Income)	—	(925.1M)	(802.7M)	(930.1M)	(1.1B)
Income Tax Expense	—	12.3M	4.0M	2.8M	1.8M
Bottom Line
Net Income	(746.0M)	(937.0M)	(806.0M)	(932.0M)	(1.1B)
Earnings from Cont. Ops	—	—	—	—	—
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	(746.0M)	(937.0M)	(806.0M)	(932.0M)	(1.1B)
Per Share
Basic EPS	(¥14)	(¥17)	(¥19)	(¥27)	(¥44)
Diluted EPS	(¥14)	—	—	—	—
Revenue Per Share	¥2	¥2	¥6	¥1	¥2
Shares
Basic Shares Outstanding	59.4M	53.7M	43.5M	34.8M	25.4M
Diluted Shares Outstanding	—	—	—	—	—
Profitability Metrics
EBITDA	—	(927.1M)	(754.6M)	(887.4M)	(1.1B)
D&A	—	13.9M	38.4M	45.6M	46.4M
EBIT	(768.0M)	(941.0M)	(793.0M)	(933.0M)	(1.1B)

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026